Microhematuria

In February this year, a major amendment to the AUA/ SUFU Microhematuria Guideline1 included language supporting the use of urine-based tumor marker (UBTM) tests in appropriately counselled intermediate risk patients. Cxbladder Triage, a UBTM test optimized for risk stratification, was included with supporting Grade A evidence from a randomized controlled trial (the STRATA study2).

Learn more about CxbladderRequest more information from the Cxbladder Team

1‎ Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004490.

2 Lotan et al. (2024). A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. The Journal of Urology Vol 212 1-8 Jul 2024.

The Utility of Cxbladder Triage in Microhematuria Evaluation: Expert Discussion

Experts discuss how Cxbladder Triage improves evaluation of microhematuria in urology practice.

2025 AUA SUFU Microhematuria Guideline

Jason Hafron, MD reviews the 2025 AUA/SUFU amendment to the microhematuria guideline.

Industry Perspective: Cxbladder Triage AUA Microhematuria Guidelines Inclusion

Jay K. Jhaveri, MD, MPH, discusses the key changes in the 2025 AUA microhematuria guidelines and their implications for clinical practice.